NO20084892L - C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose. - Google Patents

C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose.

Info

Publication number
NO20084892L
NO20084892L NO20084892A NO20084892A NO20084892L NO 20084892 L NO20084892 L NO 20084892L NO 20084892 A NO20084892 A NO 20084892A NO 20084892 A NO20084892 A NO 20084892A NO 20084892 L NO20084892 L NO 20084892L
Authority
NO
Norway
Prior art keywords
mastocytosis
kinase inhibitor
therapeutic treatment
gastrointestinal stromal
stromal tumor
Prior art date
Application number
NO20084892A
Other languages
English (en)
Other versions
NO342001B1 (no
Inventor
Carl R Illig
Shelley K Ballentine
Sanath K Meegalla
M Jonathan Rudolph
Jingsheng Chen
Mark J Wall
Kenneth J Wilson
Renee L Desjarlais
Christopher J Molloy
Carl L Manthey
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20084892L publication Critical patent/NO20084892L/no
Publication of NO342001B1 publication Critical patent/NO342001B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20084892A 2006-04-20 2008-11-20 C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose. NO342001B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79347106P 2006-04-20 2006-04-20
PCT/US2007/066985 WO2007124369A2 (en) 2006-04-20 2007-04-19 Method of inhibiting c kit kinase

Publications (2)

Publication Number Publication Date
NO20084892L true NO20084892L (no) 2009-01-06
NO342001B1 NO342001B1 (no) 2018-03-12

Family

ID=38625740

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084892A NO342001B1 (no) 2006-04-20 2008-11-20 C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose.

Country Status (22)

Country Link
EP (2) EP2397138B1 (no)
JP (1) JP5595727B2 (no)
KR (1) KR101448052B1 (no)
CN (2) CN102670605B (no)
AU (1) AU2007240400B2 (no)
BR (1) BRPI0710542B8 (no)
CA (1) CA2649755C (no)
CO (1) CO6382175A2 (no)
CR (1) CR10450A (no)
EA (1) EA016611B1 (no)
EC (1) ECSP088842A (no)
ES (2) ES2458291T3 (no)
GT (1) GT200800225A (no)
HK (1) HK1124766A1 (no)
IL (1) IL194846A (no)
MX (1) MX2008013528A (no)
MY (1) MY147226A (no)
NO (1) NO342001B1 (no)
NZ (1) NZ572200A (no)
SG (1) SG171592A1 (no)
WO (1) WO2007124369A2 (no)
ZA (1) ZA200809874B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014001079A (es) 2011-07-27 2014-09-12 Ab Science Derivados de oxazoly tiazol como inhibidores de la proteina quinasa selectiva (c-kit).
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
ES2671323T3 (es) 2013-07-22 2018-06-06 Idorsia Pharmaceuticals Ltd Derivados 1¿(piperazin¿1¿il)¿2¿([1,2,4]triazol¿1¿il)¿etanona
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
ES2709985T3 (es) 2015-01-15 2019-04-22 Idorsia Pharmaceuticals Ltd Derivados de hidroxialquil-piperazina como moduladores del receptor CXCR3
CN105753770A (zh) * 2015-05-27 2016-07-13 上海佐林生物医药有限公司 蛋白激酶抑制剂制备方法、中间体、制备方法及应用
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047277A2 (en) * 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
WO2006138155A1 (en) * 2005-06-10 2006-12-28 Janssen Pharmaceutica N.V. Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
WO2007048088A2 (en) * 2005-10-18 2007-04-26 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
NZ514918A (en) 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
BRPI0313165B8 (pt) * 2002-08-02 2021-05-25 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis e sua utilização como inibidores de c-kit
CN1950347B (zh) * 2003-10-23 2012-04-04 Ab科学公司 作为酪氨酸激酶抑制剂的2-氨基芳基噁唑化合物
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
CN1934107A (zh) * 2004-01-30 2007-03-21 Ab科学公司 作为酪氨酸激酶抑制剂的2－(3－取代芳基)氨基－4－芳基－噻唑
UA93085C2 (en) * 2006-04-20 2011-01-10 Янссен Фармацевтика Н.В. Inhibitors of c-fms kinase
EP2021335B1 (en) * 2006-04-20 2011-05-25 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
CN101466686A (zh) * 2006-04-20 2009-06-24 詹森药业有限公司 C-fms激酶抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047277A2 (en) * 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Inhibitors of c-fms kinase
NO20072489L (no) * 2004-10-22 2007-06-29 Janssen Pharmaceutica Nv Inhibitorer av C-FMS-kinase
WO2006138155A1 (en) * 2005-06-10 2006-12-28 Janssen Pharmaceutica N.V. Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
WO2007048088A2 (en) * 2005-10-18 2007-04-26 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase

Also Published As

Publication number Publication date
KR20080111545A (ko) 2008-12-23
EP2015748A2 (en) 2009-01-21
ECSP088842A (es) 2008-11-27
NO342001B1 (no) 2018-03-12
BRPI0710542A2 (pt) 2012-06-05
CA2649755A1 (en) 2007-11-01
AU2007240400A1 (en) 2007-11-01
JP5595727B2 (ja) 2014-09-24
CN101610768A (zh) 2009-12-23
ES2458291T3 (es) 2014-04-30
CN101610768B (zh) 2012-03-21
ZA200809874B (en) 2010-02-24
HK1124766A1 (en) 2009-07-24
CR10450A (es) 2009-02-23
EA200870454A1 (ru) 2009-04-28
EP2397138A1 (en) 2011-12-21
BRPI0710542B8 (pt) 2021-05-25
ES2389678T3 (es) 2012-10-30
EA016611B1 (ru) 2012-06-29
NZ572200A (en) 2011-09-30
SG171592A1 (en) 2011-06-29
IL194846A0 (en) 2009-08-03
EP2015748B1 (en) 2012-07-04
BRPI0710542B1 (pt) 2021-01-12
IL194846A (en) 2015-07-30
CN102670605A (zh) 2012-09-19
MX2008013528A (es) 2008-10-29
WO2007124369A2 (en) 2007-11-01
KR101448052B1 (ko) 2014-10-07
MY147226A (en) 2012-11-14
GT200800225A (es) 2009-05-15
JP2009534418A (ja) 2009-09-24
CO6382175A2 (es) 2012-02-15
CN102670605B (zh) 2015-07-29
AU2007240400B2 (en) 2013-08-22
WO2007124369A3 (en) 2008-03-06
CA2649755C (en) 2014-12-02
EP2397138B1 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
CY2020043I2 (el) Παγιδες gdf για χρηση στη θεραπευτικη αντιμετωπιση της αναιμιας
NO20084892L (no) C-kit kinase inhibitor for anvendelse i terapeutisk behandling av gastrointestinal stromaltumor eller mastocytose.
LTPA2020534I1 (lt) 1-((5-Heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamido dariniai, kaip fosfatidilinozitolio 3-kinazės (PI3K) inhibitoriai, naudingi proliferacinių ligų gydyme
HK1254663A1 (zh) 用於實體腫瘤的治療的布魯頓酪氨酸激酶的抑制劑
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
IL202505A (en) 2-oxo-3-benzyl-benzoxazole-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors, drugs containing them and their uses
DK2044026T3 (da) Fremgangsmde til behandling af cerebral glioma tumor
CY2016017I1 (el) Συνθεση για θεραπεια πνευμονικης υπερτασης
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE453635T1 (de) C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
NO20091183L (no) Derivater av 4-(N-azacykloalkyl)-anilider, fremgangsmåte for fremstilling av slike forbindelser, preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for forhindring eller behandling av sykdom
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
HK1148284A1 (en) Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions hif
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE502944T1 (de) 2-amino-5,7-dihydro-6h-pyrroloä3,4- düpyrimidinderivate als hsp-90-inhibitoren zur behandlung von krebs
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0822129A2 (pt) Inibidores de aldh-2c no tratamento de vício.
FI20095600A (fi) Koostumus ihosairauksien hoitoa varten
DK3156057T3 (da) Delmopinol-belagt dyretyggeartikel til anvendelse til forebyggelsen eller behandlingen af halitosis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees